Piramal Pharma Announces Q2 and H1 FY27 Results

Piramal Pharma reported H1 FY27 revenue up 23% and EBITDA margin expansion of over 350 bps, led by 28% growth in CDMO and 24% in CHG; Consumer Healthcare grew 14%. Management said H2 is typically stronger and cited a healthy order book.Material DetailsContext by AI AnalystThis is a mid-cycle confir…